ArticleESMO gastrointestinal oncology2025

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m

J W Valle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.